Cancer is currently the biggest challenge facing medicine and medical research. PPF Group’s Sotio, one of a handful of ambitious biotechnology companies in Central Europe, is tackling one of the toughest tasks of civilization today: developing cures for several types of cancer. The research is extremely expensive and potentially as unrewarding as it is costly. Sotio costs PPF Group hundreds of millions of crowns a year, but the company has a strong hand it wants to play over the next twelve months. “This will be a landmark year largely determining what happens next for Sotio,” says Radek Špíšek, CEO of the company that might bring the world closer to longevity, as long as it has the funding to do so.